FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine and relates to a stable composition for intrathecal administration, comprising an arylsulfatase A (ASA) protein, polysorbate and phosphate. Said phosphate is present in an amount of not more than 10 mM. Group of inventions also relates to a method for treating metachromatic leukodystrophy disease, comprising a step of intrathecal administration to a subject in need of said composition.
EFFECT: group of inventions ensures successful intrathecal administration of the composition without significant toxicity and immune response.
30 cl, 9 ex, 46 tbl, 56 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS AND COMPOSITIONS FOR DELIVERY OF ARYLSULFATASE A TO CNS | 2011 |
|
RU2783380C2 |
| MEDICAL AGENTS DELIVERY TO THE CENTRAL NERVOUS SYSTEM | 2011 |
|
RU2626514C2 |
| METHODS AND COMPOSITIONS FOR DELIVERY OF IDURONATE-2-SULPHATASE TO CNS | 2011 |
|
RU2774112C2 |
| METHODS AND COMPOSITIONS FOR CNS DELIVERY OF IDURONATE-2-SULFATASE | 2011 |
|
RU2660348C2 |
| THERAPEUTIC TARGETED FUSION PROTEINS BASED ON LYSOSOMAL ENZYMES, RELEVANT COMPOSITIONS AND THEIR APPLICATIONS | 2017 |
|
RU2751235C2 |
| TARGETED THERAPEUTIC LYSOSOMAL ENZYME FUSION PROTEINS AND USES THEREOF | 2013 |
|
RU2680581C2 |
| TPP1 PREPARATIONS AND METHODS OF TREATING CLN2 DISEASE | 2016 |
|
RU2733464C2 |
| RECOMBINANT GENETIC CONSTRUCT, ADENO-ASSOCIATED VIRUS FOR THERAPY OF METACHROMATIC LEUKODYSTROPHY | 2023 |
|
RU2821568C1 |
| DRUG FOR THE TREATMENT OF METACHROMATIC LEUKODYSTROPHY AND A METHOD FOR ITS TREATMENT | 2021 |
|
RU2769577C1 |
| HAPTOGLOBIN FOR USE IN TREATMENT OF UNFAVORABLE SECONDARY NEUROLOGICAL OUTCOME FOLLOWING HAEMORRHAGIC STROKE | 2020 |
|
RU2818474C2 |
